Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human RPS6KA1 Antibodies:
anti-Mouse (Murine) RPS6KA1 Antibodies:
anti-Rat (Rattus) RPS6KA1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal RPS6KA1 Primary Antibody for DB, WB - ABIN1881765
Roux, Ballif, Anjum, Gygi, Blenis: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. in Proceedings of the National Academy of Sciences of the United States of America 2004
Show all 5 Pubmed References
Polyclonal RPS6KA1 Primary Antibody for WB - ABIN4948290
Eisenmann, VanBrocklin, Staffend, Kitchen, Koo: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. in Cancer research 2003
Show all 3 Pubmed References
Human Polyclonal RPS6KA1 Primary Antibody for ELISA, WB - ABIN1043904
Chaturvedi, Poppleton, Stringfield, Barbier, Patel: Subcellular localization and biological actions of activated RSK1 are determined by its interactions with subunits of cyclic AMP-dependent protein kinase. in Molecular and cellular biology 2006
FASN (show FASN Antibodies)-induced S6 kinase (show RPS6KB1 Antibodies) facilitates USP11 (show USP11 Antibodies)-eIF4B (show EIF4B Antibodies) complex formation for sustained oncogenic translation in diffuse large B-cell lymphoma.
Polymorphism in p90Rsk gene is associated with Fetal Alcohol Spectrum Disorders.
The results suggested a possible link between tRNALeu overexpression and RSK1/MSK2 activation and ErbB2 (show ERBB2 Antibodies)/ErbB3 (show ERBB3 Antibodies) signaling, especially in breast cancer.
Phosphorylation at Ser732 affects ribosomal S6 kinase 1 (RSK1) C-terminal tail (CTT (show TNNT2 Antibodies)) binding.
These results suggest that RSK1 protects P-gp (show ABCB4 Antibodies) against ubiquitination by reducing UBE2R1 (show CDC34 Antibodies) stability.
Genetic or pharmacologic inhibition of p90RSK in ganetespib-resistant cells restored sensitivity to ganetespib, whereas p90RSK overexpression induced ganetespib resistance in naive cells, validating p90RSK as a mediator of resistance and a novel therapeutic target
Data suggest that UBR5 (show UBR5 Antibodies) down-regulates levels of TRAF3 (show TRAF3 Antibodies), a key component of Toll (show TLR4 Antibodies)-like receptor signaling, via the miRNA pathway; p90RSK is an upstream regulator of UBR5 (show UBR5 Antibodies); p90RSK phosphorylates UBR5 (show UBR5 Antibodies) as required for translational repression of TRAF3 (show TRAF3 Antibodies) mRNA. (UBR5 (show UBR5 Antibodies) = ubiquitin protein ligase E3 component n-recognin 5 (show UBR5 Antibodies) protein; TRAF3 (show TRAF3 Antibodies) = TNF receptor-associated factor 3 (show TRAF3 Antibodies); p90RSK = 90 kDa ribosomal protein S6 (show RPS6 Antibodies) kinase (show RPS6KB1 Antibodies))
Data indicate that BTG2 (show BTG2 Antibodies), MAP3K11 (show MAP3K11 Antibodies), RPS6KA1 and PRDM1 (show PRDM1 Antibodies) as putative targets of microRNA miR (show MLXIP Antibodies)-125b.
VEGF-A (show VEGFA Antibodies) driven Mdm2 (show MDM2 Antibodies) phosphorylation on Ser166 is dependent on the ERK1/2/p90RSK signaling pathway in primary human endothelial cells.
The p90RSK has an essential role in promoting tumor growth and proliferation in non-small cell lung cancer (NSCLC). BID (show BID Antibodies) may serve as an alternative cancer treatment in NSCLC.
In hippocampal neurons of wild-type mice, pP90RSK translocates into the nucleus upon stimulation with forskolin (left), whereas in Period1-knockout (Per1 (show PER1 Antibodies)(-/-) ) mice (right) the kinase is trapped at the nuclear periphery
Data show that the phosphoinositide-dependent kinase 1 (PDK1 (show PDPK1 Antibodies))-p90 (show GPAM Antibodies) kDa ribosomal S6 kinases (Rsks) Rsk1/2 pathway is critical for establishment and maintenance of a normal Langerhans cells (LC) network.
IL-6 (show IL6 Antibodies) induces the activation of the Stat3 (show STAT3 Antibodies) signaling and promotes the downmodulation of the p90RSK/eEF2 (show EEF2 Antibodies) and mTOR (show FRAP1 Antibodies)/p70S6K (show RPS6KB1 Antibodies) axes, while it does not affect the activation of AKT (show AKT1 Antibodies).
analysis of p38 (show CRK Antibodies)-MK2 (show KCNA2 Antibodies)-activated Rsk signaling in toll (show TLR4 Antibodies)-like receptor-stimulated dendritic cells
These data indicate that aripiprazole and quetiapine signal to specific nuclear targets of ERK (show EPHB2 Antibodies), which for quetiapine occurs via an EGFR (show EGFR Antibodies)-linked mechanism, possibly indicating involvement of this system in its action.
hypoxia/reoxygenation (H/R)-mediated decrease in PKARIalpha protein levels leads to activation of RSK1, which via phosphorylation of NHE1 (show SLC9A1 Antibodies) induces cardiomyocyte apoptosis.
RSK1 Cys223 glutathionylation may contribute to regulate the levels of nitric in the brain.
Our study highlights the importance of the p90RSK/ERK5 (show MAPK7 Antibodies) module as a critical mediator of endothelial dysfunction in diabetes mellitus and atherosclerosis formation.
Results show increased protein levels of Rsk1 and Rsk2 (show RPS6KA3 Antibodies) in the striatum of Huntington disease (show HTT Antibodies) mice and and striatal cells transfected with full-length mutant Huntingtin (show HTT Antibodies).
Type I keratin (show KRT12 Antibodies) 17 (show KRT17 Antibodies) protein is phosphorylated on serine 44 by p90 (show GPAM Antibodies) ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion
This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 nonidentical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
90 kDa ribosomal protein S6 kinase 1
, MAP kinase-activated protein kinase 1a
, MAPK-activated protein kinase 1a
, MAPKAP kinase 1a
, S6K-alpha 1
, dJ590P13.1 (ribosomal protein S6 kinase, 90kD, polypeptide 1)
, p90-RSK 1
, ribosomal S6 kinase 1
, ribosomal protein S6 kinase alpha 1
, ribosomal protein S6 kinase alpha-1
, ribosomal protein S6 kinase, 90kD, polypeptide 1; Ribosomal protein S6 kinase, 90kD, 1
, MAP kinase-activated protein kinase 1
, MAPK-activated protein kinase 1
, MAPKAP kinase 1
, ribosomal protein S6 kinase 2 alpha
, ribosomal protein S6 kinase II alpha
, S6 protein kinase (Rsk-1)
, S6 kinase II beta
, ribosomal protein S6 kinase 2 beta
, ribosomal protein S6 kinase II beta
, ribosomal protein S6 kinase a, polypeptide 1